EGFR and neoplasm: Compared with EGFR mutation detection in tumor tissue DNA, the total concordance rate of ctDNA detected by SuperARMS was higher than that of ARMS (79.5% [95% CI: 73.7%, 84.4%] vs. 69% [95% CI: 62.0%, 80.3%], p = 0.04), especially in patients in stage I‐IIIA (85.7% [95% CI: 60.1%, 96.0%] vs. 50.0% [95% CI: 9.5%, 90.6%], p = 0.4) compared with patients in stage IIIB‐IV (79.1% [95% CI: 73.0%, 84.2%] vs. 69.4% [95% CI: 59.7%, 77.6%], p = 0.04).